{"url_path":"/sec/aurx/8-k/2026-06-03/item-3-02","section_key":"item-3-02","section_title":"Item 3.02 Unregistered Sale of Equity Securities.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1091596/0001437749-26-019199-index.html","accession_number":"0001437749-26-019199","cik":"0001091596","ticker":"AURX","issuer_name":"Nuo Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1091596/0001437749-26-019199-index.html","primary_entity_key":"0001091596","primary_entity_name":"Nuo Therapeutics, Inc."},"word_count":111,"has_tables":true,"body_markdown":"**Item 3.02 Unregistered Sale of Equity Securities.**\n\n \n\nTo the extent required by Item 3.02 of Form 8-K, the information contained in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. The offer and sale of the Commitment Supplemental Warrants, Origination Interim Warrants, Capital Interim Warrants, Origination Restated Second Warrants, Capital Restated Second Warrants, Prepayment Restated Warrants, and Interest Warrants, and the shares of the Company’s common stock underlying all such warrants, have not been registered under the Securities Act, and such securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act."}